Jean‐Yves Blay

Research interests

Publications

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2016 · 10.1016/s0140-6736(15)01283-0

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1502309

• Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

  Cancer Cell · 2014 · 10.1016/j.ccr.2014.05.016

• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70063-4

• Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70277-8

• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)60651-5

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61857-1

• Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70010-3

• Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70071-1

• Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.3223

• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

  Cancer Research · 2009 · 10.1158/0008-5472.can-08-3845

• Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

  Cancer Research · 2009 · 10.1158/0008-5472.can-08-2360

• Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.18.0802

• Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.17.3146

• NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

  Journal of the National Comprehensive Cancer Network · 2007 · 10.6004/jnccn.2007.2002

• KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

  European Journal of Cancer · 2006 · 10.1016/j.ejca.2006.01.030

• Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Annals of Oncology · 2005 · 10.1093/annonc/mdi127

• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  The Journal of Experimental Medicine · 2005 · 10.1084/jem.20051511

• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  The Lancet · 2004 · https://doi.org/10.1016/s0140-6736(04)17098-0

• Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.09.139

Current projects

No projects listed.